Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

计划入组 40 人 · 首次发布于 2023 年 5 月 6 日

Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

首次发布于 2019 年 11 月 25 日

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

计划入组 66 人 · 首次发布于 2018 年 7 月 11 日

GalNAc-UGT1A1-RNAi

GalNAc-EON-11

F12 GalNAc-siRNA

NUI Galway

Ireland

GALENA BIOPHARMA, INC.

United States

PerkinElmer Wallac Oy

Korro Bio Advances RNA Editing Platform with KRRO-121 Nomination and $85 Million Financing

Tangram Therapeutics Advances Novel RNAi Therapy TGM-312 to Clinical Trials for MASH Treatment

Korro Bio's RNA Editing Drug Shows Promise but Falls Short of Efficacy Targets in Alpha-1 Antitrypsin Deficiency Trial